Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of peginterferon alfa-1b injection in patients with herpes zoster
CTR20221853Phase 2Active
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Oct 2022
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of peginterferon alfa-1b in herpes zoster (HZ), sponsored by Shanghai Institute of Biological Products. Started Oct 2022; status: active.
02
Drugs
peginterferon alfa-1b
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on CTR20221853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221853.